Public Health Triumphs: Delhi High Court Upholds FSSAI Ban on Misleading 'ORS' Labeled Beverages

New Delhi – In a significant affirmation of regulatory authority and public health principles, the Delhi High Court has declined to interfere with the Food Safety and Standards Authority of India's (FSSAI) comprehensive ban on food and beverage products misleadingly using the term "ORS" (Oral Rehydration Solution) in their branding. Justice Sachin Datta, presiding over the matter, underscored that "public health considerations is paramount," effectively prioritizing consumer safety over the commercial interests of major pharmaceutical and consumer health companies.

The decision came during the hearing of a petition filed by Dr. Reddy's Laboratories (DRL), which challenged FSSAI orders from October 14 and 15. These orders had withdrawn prior approvals that permitted the use of the term 'ORS' with prefixes or suffixes in registered trademarks for electrolyte drinks, such as DRL's "Rebalanz VITORS". The court's firm stance reinforces the FSSAI's statutory power to regulate misbranding and misleading advertising under the Food Safety and Standards (FSS) Act, 2006.

The Court's Unwavering Position: No Interim Relief

Dr. Reddy's Laboratories, through its counsel, informed the court that it had ceased manufacturing new batches of "Rebalanz VITORS" and was prepared to rebrand the product. However, the company sought an interim arrangement to sell its existing stock already in the market to avoid financial losses.

This request was vehemently opposed by the FSSAI, represented by Additional Solicitor General (ASG) Chetan Sharma and Central Government Standing Counsel (CGSC) Ashish Dixit. Justice Datta unequivocally sided with the regulator, refusing to grant any permission that could perpetuate a risk to public health.

"It is a health hazard… This embargo will continue. I am not doing away with the embargo, considering the public health concerns," Justice Datta orally remarked, making it clear that no interim relief would be granted. "We can’t allow public health risk and allow you to continue in the market."

Instead of granting a judicial stay, the court directed DRL to make a formal representation to the FSSAI regarding its existing stock and rebranding plans (now proposed as ‘Rebalanz Vitenergy’). The court indicated it would set a timeline for the FSSAI to consider this representation, thereby upholding the administrative process and the regulator's primary jurisdiction in such matters.

FSSAI's Rationale: The Hazard of Misinformation

The legal battle stems from the FSSAI's determination that many popular electrolyte drinks branded with "ORS" do not conform to the World Health Organization (WHO) recommended formula for medical-grade Oral Rehydration Solution. The WHO-prescribed ORS is a precise, low-sodium, low-glucose formulation designed to combat severe dehydration, particularly from conditions like diarrhea.

In contrast, many commercial beverages using the "ORS" moniker are high-sugar, fruit-flavored drinks. The FSSAI's reasoned order, issued on October 30 after considering a representation from JNTL Consumer Health India (a subsidiary of Kenvue, formerly Johnson & Johnson), detailed the severe health risks posed by this confusion. The regulator's order noted:

"The ingestion of a high-sugar electrolyte drink can worsen dehydration rather than alleviate it, by drawing water out of body cells through osmotic imbalance. The risk is further aggravated among children, diabetic patients, and elderly persons, who represent the most vulnerable categories of consumers."

The FSSAI concluded that such branding practices are not merely misleading but constitute a "direct and immediate risk to human health." The authority found that using the term "ORS," even with a prefix or suffix, violates Sections 23 (Misbranded food) and 24 (Restrictions of advertisement and prohibition as to unfair trade practices) of the FSS Act, 2006, read with labeling and advertising regulations. The regulator also dismissed the effectiveness of disclaimers, noting that the dominant "ORS" branding and similar packaging often cause consumers, particularly laypersons, to overlook or misunderstand fine print.

Legal Implications for Food and Drug Law Practitioners

The Delhi High Court's decision offers several key takeaways for the legal community, particularly those advising clients in the pharmaceutical, food, and Fast-Moving Consumer Goods (FMCG) sectors:

1. Judicial Deference to Regulatory Expertise: The court demonstrated significant deference to the FSSAI's scientific and public health-based reasoning. Justice Datta's refusal to "disturb" the regulator's embargo signals that courts are hesitant to substitute their judgment for that of a specialized statutory body on technical matters, especially when public safety is at stake. This reinforces the principle that the primary remedy for an aggrieved party is to engage with the administrative process of the regulator.

2. The Limits of Trademark Protection: The case serves as a critical reminder that a registered trademark does not provide an unassailable right to use a name that is found to be misleading or in contravention of other statutes. The FSSAI's action, upheld by the court, establishes that the FSS Act's provisions against misbranding can override trademark rights when a name is deemed deceptive and harmful to consumers.

3. Strict Scrutiny of Health-Related Claims: Companies using medically significant terms like "ORS" in their branding for non-medical products can expect intense regulatory scrutiny. The FSSAI's stance indicates a zero-tolerance policy for branding that could cause a consumer to mistake a lifestyle beverage for a therapeutic product. Legal advisors must counsel clients to be exceedingly cautious with brand names and marketing claims that touch upon health and wellness.

4. Procedural Pathway for Redressal: The court's direction for Dr. Reddy's to approach the FSSAI with a representation clarifies the appropriate procedural pathway. Rather than seeking immediate judicial intervention to continue sales, the court has channeled the dispute back to the regulatory body, which is empowered to make a reasoned decision based on the specific facts and proposals presented by the company.

This episode highlights a growing trend of regulatory activism aimed at protecting consumers from misleading information, a trend now robustly supported by the judiciary. For legal professionals, this case underscores the need for a proactive, compliance-focused approach to product branding and marketing, ensuring that commercial creativity does not compromise public health or contravene the stringent provisions of India's food safety laws.